Kannan Rangaramanujam, Ph.D.
Co-founder, Board Observer, Co-Director, Center for Nanomedicine, Professor of Ophthalmology at Johns Hopkins University
Dr. Rangaramanujam is a Co-founder, Board Observer of Ashvattha Therapeutics and is the Arnall Patz distinguished Professor of Ophthalmology and Co-director of Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine. The hydroxyl dendrimer platform technology and the associated dendrimer-drug conjugates that formed the basis of Ashvattha were discovered and developed through the collaborative work of his and Sujatha Kannan’s research groups at Johns Hopkins and Wayne State University. They and other collaborators at Hopkins extensively validated the dendrimer platform through extensive studies in 50+ mouse, rat, rabbit, canine and primate animal models, and human tissue, supported by substantial funding by the NIH for 15+ years. Dr. Rangaramanujam is an author of 100+ patents (issued and pending, licensed, most licensed to Ashvattha), and 130+ peer-reviewed publications. He has won several recognitions, including fellowship of the American Institute of Medical and Biological Engineers (AIMBE) and NSF CAREER awards. As a Co-founder and Board Member, and the initial CTO of Ashvattha, he worked closely with the company on the clinical development and validation of Ashvattha’s lead candidates in neurology, ophthalmology, and oncology.